The short answer
Retatrutide activates the GIP, GLP-1 and glucagon receptors from one sequence. All three are class B G-protein-coupled receptors within the glucagon receptor family, sharing enough structural similarity that a single engineered peptide can engage all three.
Key facts
- Receptors
- GIPR, GLP-1R, GCGR
- Receptor class
- Class B GPCRs
- Family
- Glucagon receptor family
- Design
- Balanced activity across all three
- Scaffold
- Modified GIP
- Reference
- Coskun, Cell Metab 2022
Why three receptors can share one ligand
GIP, GLP-1 and glucagon are related peptide hormones, and their receptors form a structurally related family. That common ancestry means the binding surfaces are similar enough that a sequence can be engineered to satisfy all three, not easily, but possibly. Attempting the same across unrelated receptor families would not be realistic.
Why balance is the hard problem
Similar is not identical. A substitution improving affinity at one receptor frequently reduces it at another, so the design process is a constrained optimisation across three simultaneous requirements rather than three independent ones. Coskun and colleagues describe reaching balanced activity across the three, and that balance is the achievement the paper reports.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What each receptor contributes
GLP-1 receptor agonism drives satiety and glucose-dependent insulin secretion. GIP receptor agonism adds effect through mechanisms still debated; the GIP paradox, where both agonism and antagonism appear to help, is unresolved. Glucagon receptor agonism increases energy expenditure and drives hepatic lipid oxidation, offset by the GLP-1 component's glucose-lowering effect.
Why adding glucagon is not self-defeating
Glucagon raises blood glucose, which sounds like the wrong direction. The resolution is that it also increases resting energy expenditure and mobilises hepatic fat, and with sufficient concurrent GLP-1 agonism the glycaemic effect is offset while those remain. Oxyntomodulin, an endogenous GLP-1/glucagon dual agonist, demonstrates that the body already uses this combination.
Why this produces the largest reported effect
More receptors engaged has consistently meant more weight reduction across this field: GLP-1 alone, then GLP-1 plus GIP, then all three. It has also consistently meant more gastrointestinal adverse effects, which is the trade-off the whole class shares. Retatrutide sits at the far end of both.
What remains unsettled
How much each receptor contributes. Because the three activities cannot be separated within one molecule, attributing the observed effect between them requires comparison against compounds engaging fewer receptors. That is what TRIUMPH-5, comparing retatrutide against tirzepatide, is designed to inform.
Frequently asked questions
How can one peptide activate three receptors?
GIPR, GLP-1R and GCGR belong to one structurally related family, so their binding surfaces are similar enough that an engineered sequence can satisfy all three.
Why include glucagon agonism at all?
It raises energy expenditure and mobilises hepatic fat. Sufficient GLP-1 agonism offsets its glucose-raising effect, and oxyntomodulin shows the body uses this combination naturally.
Which receptor contributes most?
Not established. The activities cannot be separated within one molecule, which is part of what a head-to-head against tirzepatide would inform.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al., LY3437943. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubMedJastreboff AM et al. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedThe Paradox and Future of GLP-1/GIP Combination Therapies. Annu Rev Nutr 2026 (PMID 42166683)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- Retatrutide and AlcoholNo interaction study exists for retatrutide specifically. What the GLP-1 class literature reports about alcohol, and why the honest answer is narrow.
- Is There a Retatrutide Tablet or Pill?No oral retatrutide exists in any trial or any market. Why a 39-residue peptide cannot simply be pressed into a tablet, and what is being sold under that name.
- Fake Retatrutide and What a Certificate Can ProvePurity, identity and quantity are three separate questions and most certificates answer one. What HPLC and mass spectrometry establish, and what neither does.
- Is Retatrutide Legal?Retatrutide holds no marketing authorisation anywhere, making it unapproved rather than controlled. Two separate legal regimes, constantly confused.
- Retatrutide Side Effects Reported So FarGastrointestinal events dominate, and they rise with dose. What TRIUMPH-1 and the Phase 2 work reported, and which discussed effects have no trial support.